Physician profile
Neil E Toback
NPI 1942225610
$3,088.09
in general payments reported to CMS, 2019-2025
18 companies · $650 in 2025
The $650 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $37.52 · 2021: $189 · 2022: $684 · 2023: $660 · 2024: $738 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,028 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,028.01 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $665.52 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $655.07 | 2019-2025 | |
| Leo Pharma INC. | $324.79 | 2019-2025 | Adbry |
| Dermavant Sciences, INC. | $300.38 | 2023-2024 | Vtama |
| Genzyme Corporation | $206.04 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $175.51 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $149.18 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $104.75 | 2022-2024 | Tremfya |
| Ucb, INC. | $100.96 | 2022-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $77.34 | 2019-2025 | Cabtreo |
| Amgen INC. | $68.23 | 2023-2025 | Otezla, Otezla |
| Epi Health, LLC | $59.72 | 2022 | |
| Incyte Corporation | $52.69 | 2022-2023 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $48.78 | 2022-2024 | Libtayo |
| Journey Medical Corporation | $40.45 | 2020-2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $25.35 | 2023 | Xeomin |
| Biofrontera INC. | $24.78 | 2022 | |
| Organon LLC | $8.55 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Toback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.